Abstract: The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of conditions characterized by excessive activity and/or migration of monocytes and/or macrophages. Suitable agents may include class III SLRPs such as opticin. Methods of treatment using agents able to promote class III SLRP activity are also provided.

Abstract: Certain embodiments of the present invention provide a method and system for improved static address translation. Certain embodiments include a method for address translation in a network, wherein the network includes a device associated with an identifier and assigned a dynamic address. The method includes matching the identifier for the device to a static address; creating an address mapping between the dynamic address assigned to the device and the static address; and transmitting data to and from the device using the address mapping. The method may also include transmitting a record indicating a presence of the device on the network, wherein the record includes the identifier for the device. Additionally, the method may include providing the address mapping to a router for routing data between the device and another entity. The method may automatically create the address mapping between the dynamic address and the static address, for example.

Abstract: Use of factor XIII for treating hemophilia B. A patient having hemophilia B is treated by administering factor XIII, generally in conjunction with factor IX.

Abstract: A method is provided for fabricating microelectrodes and microelectrode arrays by etching in an acid solution. Glass wafers are diced into a desired shape to form narrow probes, which are immersed in the acid solution. An organic layer on top of the acid solution forms a meniscus at the point of contact with the probes, and the taper angle on the etched probes will depend on this meniscus angle. After etching, the tapered probes are coated with a conductive layer, followed by an insulating layer over most of their length so as to leave a small conductive area exposed at the tip. The glass wafer containing the probes is then mounted on a printed circuit board carrier.

Abstract: A method is provided for fabricating microelectrodes and microelectrode arrays by etching in an acid solution. Glass wafers are diced into a desired shape to form narrow probes, which are immersed in the acid solution. An organic layer on top of the acid solution forms a meniscus at the point of contact with the probes, and the taper angle on the etched probes will depend on this meniscus angle. After etching, the tapered probes are coated with a conductive layer, followed by an insulating layer over most of their length so as to leave a small conductive area exposed at the tip. The glass wafer containing the probes is then mounted on a printed circuit board carrier.

Abstract: The present invention relates to peptide, polynucleotide and fusion proteins for use as inhibitors in hemostasis. These inhibitors are members of the family of proteins bearing a collagen-like domain and a globular domain. The inhibitors are useful for promoting blood flow in the vasculature by reducing thrombogenic and complement activity. The inhibitors are also useful for pacify collagenous surfaces and modulating wound healing.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp3, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zacrp3 polypeptides.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zdint1, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are believed to be cell-cell interaction modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the zdint1 polypeptides.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zacrp2, a novel member of the family of proteins bearing a collagen-like domain and a C1q domain. The polypeptides and polynucleotides encoding them, are involved in dimerization or oligomerization and may be used in the study thereof. The present invention also includes antibodies to the zacrp2 polypeptides.

Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.

Abstract: The present invention provides two members of a new family of human proteins, designated as “Zven.” The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes.

Abstract: The present invention is directed to polynucleotides, polypeptides, peptides, variants and uses thereof for novel peptide fragments which have homology to motilin. Tissue distribution of the mRNA for the novel polypeptide fragment is specific to the stomach, small intestine and pancreas. Binding of the peptide fragment has been shown in kidney and small intestine. The present invention further includes agonists, antagonists, variants, antibodies and host cells expressing the cDNA encoding the novel SGIP peptide.

Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.

Abstract: Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically. If the factor XIII is administered locally, it can be activated or non-activated and may be administered in conjunction with activated thrombin.

Abstract: The present invention provides novel uses two members of a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes.

Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.

Abstract: The present invention relates to polynucleotide related to the zsig33 peptide, including agonists, antagonists, and antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.

Abstract: There is disclosed a method for treating textiles comprising applying to the textile an enzyme having a specific activity towards the textile, under conditions such that there is substantially no mechanical agitation.

Abstract: This invention relates to compositions comprising a class of new chemical compounds which can be applied to a textile material preferably composed of fibers of cellulose, regenerated cellulose or a cellulose ester or ether, to contribute an attractive softening effect. The new compounds possess a hydrophilic solubilising group linked to each of two triazine rings and an average of two hydrophobic groups and two halogen substituents per molecule. After impregnation with the compositions of the invention the compounds are fixed to the textile material by heating at 100.degree.-150.degree.C.